Methods for treating headache using antagonist antibodies directed against calcitonin gene-related peptide

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9884908
SERIAL NO

15588512

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms, including headaches (e.g., migraine, cluster headache, and tension headache) and hot flushes, by administering an anti-CGRP antagonist antibody. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
TEVA PHARMACEUTICALS INTERNATIONAL GMBH8645 RAPPERSWIL-JONA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Abdiche, Yasmina Noubia Mountain View, US 31 1194
Collier, Sierra Jones Menlo Park, US 18 463
Pons, Jaume San Bruno, US 98 2170
Poulsen, Kristian T San Francisco, US 19 628
Rosenthal, Arnon Woodside, US 193 2102
Zeller, Joerg Ann Arbor, US 43 1070

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Aug 6, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Aug 6, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00